PT3635408T - Métodos de previsão da utilidade de modificações de aminoácidos específicas de uma doença para imunoterapia - Google Patents

Métodos de previsão da utilidade de modificações de aminoácidos específicas de uma doença para imunoterapia

Info

Publication number
PT3635408T
PT3635408T PT187283890T PT18728389T PT3635408T PT 3635408 T PT3635408 T PT 3635408T PT 187283890 T PT187283890 T PT 187283890T PT 18728389 T PT18728389 T PT 18728389T PT 3635408 T PT3635408 T PT 3635408T
Authority
PT
Portugal
Prior art keywords
immunotherapy
predicting
usefulness
methods
amino acid
Prior art date
Application number
PT187283890T
Other languages
English (en)
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59227704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3635408(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of PT3635408T publication Critical patent/PT3635408T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT187283890T 2017-06-09 2018-06-01 Métodos de previsão da utilidade de modificações de aminoácidos específicas de uma doença para imunoterapia PT3635408T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2017/064140 WO2018224166A1 (en) 2017-06-09 2017-06-09 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Publications (1)

Publication Number Publication Date
PT3635408T true PT3635408T (pt) 2025-07-31

Family

ID=59227704

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187283890T PT3635408T (pt) 2017-06-09 2018-06-01 Métodos de previsão da utilidade de modificações de aminoácidos específicas de uma doença para imunoterapia

Country Status (26)

Country Link
US (2) US12270813B2 (pt)
EP (2) EP3635408B1 (pt)
JP (3) JP7396903B2 (pt)
KR (1) KR102560750B1 (pt)
CN (1) CN110741260B (pt)
AR (1) AR112601A1 (pt)
AU (2) AU2018279117B2 (pt)
BR (1) BR112019022349A2 (pt)
CA (1) CA3066308A1 (pt)
DK (1) DK3635408T3 (pt)
ES (1) ES3037112T3 (pt)
FI (1) FI3635408T3 (pt)
HR (1) HRP20250791T8 (pt)
HU (1) HUE072622T2 (pt)
IL (2) IL271031B2 (pt)
LT (1) LT3635408T (pt)
MA (1) MA49246A (pt)
MX (2) MX2024014422A (pt)
PL (1) PL3635408T3 (pt)
PT (1) PT3635408T (pt)
RS (1) RS67008B1 (pt)
SG (2) SG11201911618UA (pt)
SI (1) SI3635408T1 (pt)
SM (1) SMT202500278T1 (pt)
TW (2) TW202426040A (pt)
WO (2) WO2018224166A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
AU2018219862B2 (en) * 2017-02-07 2020-09-17 Nant Holding IP, LLC Maximizing T-cell memory and compositions and methods therefor
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
WO2021030030A1 (en) * 2019-08-09 2021-02-18 Nantomics, Llc Machine methods to determine neoepitope payload toxicity
EP4046651A1 (en) * 2021-02-23 2022-08-24 baseclick GmbH Method for producing an mrna tumor vaccine
CN115620810B (zh) * 2022-12-19 2023-03-28 北京诺禾致源科技股份有限公司 基于第三代基因测序数据的外源插入信息的检测方法和装置
CN116189880A (zh) * 2023-01-21 2023-05-30 中国医学科学院北京协和医院 一种肺腺癌脑转移的预测指标及预测方法和应用
JP7413583B1 (ja) * 2023-03-31 2024-01-15 株式会社電通 魚の品質判定システム
IL326727A (en) * 2023-08-23 2026-04-01 Lg Chemical Ltd A method for neoantigen selection for personalized cancer vaccine development
WO2025191449A1 (en) 2024-03-11 2025-09-18 Instadeep Ltd Systems and methods for machine learning-based genome annotation
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3776808D1 (de) 1986-04-08 1992-04-02 Illinois Tool Works Verpackung.
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5824315A (en) 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
ES2180045T3 (es) 1996-04-19 2003-02-01 Us Gov Sec Health Peptidos ras mutados para la generacion de linfocitos t citotoxicos cd8+.
JP4108126B2 (ja) 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
CN1138533C (zh) 1996-09-13 2004-02-18 利普森有限公司 脂质体
ATE229810T1 (de) 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
TR200001253T2 (tr) 1997-11-06 2000-11-21 Roche Diagnostics Gmbh Tümöre özel antijenler
WO1999034014A2 (en) 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
AU1774299A (en) 1997-12-24 1999-07-19 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
EP1117430A1 (en) 1998-10-05 2001-07-25 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
CN100352921C (zh) 1999-05-06 2007-12-05 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
CA2384987A1 (en) 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
EP1222289B1 (en) 1999-10-20 2008-04-16 The Johns Hopkins University School Of Medicine Chimeric immunogenic compositions and nucleic acids encoding them
EP1261704B1 (en) 1999-11-30 2009-07-01 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1242108B1 (en) 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
WO2001055393A2 (en) 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
DK1276896T3 (da) 2000-04-28 2010-10-18 Mannkind Corp Epitop-synkronisering i antigen-præsenterende celler
WO2001093902A2 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
JP5087201B2 (ja) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
NZ533237A (en) 2001-11-26 2005-11-25 Univ Queensland Flavivirus vaccine delivery system
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003059381A2 (en) 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
WO2003070162A2 (en) 2002-02-19 2003-08-28 Genzyme Corporation Par-3 compounds for therapy and diagnosis and methods for using same
WO2003078595A2 (en) 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
WO2003106692A2 (en) 2002-06-13 2003-12-24 Merck Patent Gmbh Methods for the identification of all-antigens and their use for cancer therapy and transplantation
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
AU2003267401A1 (en) 2002-10-02 2004-04-23 F. Hoffmann-La Roche Ag Novel mhc ii associated peptides
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
WO2005023295A2 (en) 2003-09-10 2005-03-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
WO2005039533A1 (en) 2003-10-15 2005-05-06 Medigene Ag Method of administering cationic liposomes comprising an active drug
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
EP1589030A1 (en) 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
CA2592972A1 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
EP1715346A1 (en) 2005-04-22 2006-10-25 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method of identifying CD4+ T cell antigens
ES2367643T3 (es) * 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este.
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2009532664A (ja) 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
WO2007106523A2 (en) 2006-03-13 2007-09-20 Veridex, Llc Propagation of primary cells
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20090304711A1 (en) 2006-09-20 2009-12-10 Drew Pardoll Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
CN101687022B (zh) 2007-03-26 2016-09-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
DK2276486T3 (da) 2008-03-24 2013-11-25 4Sc Discovery Gmbh Nye substituerede imidazo-quinoliner
EP2276495B1 (en) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US20110195090A1 (en) 2008-10-11 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Method of making a vaccine
MX2011005691A (es) 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
CA2769670C (en) 2009-07-31 2018-10-02 Ethris Gmbh Rna with a combination of unmodified and modified nucleotides for protein expression
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
EP3892295B1 (en) 2011-05-24 2023-04-26 BioNTech SE Individualized vaccines for cancer
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US20150030576A1 (en) 2012-01-10 2015-01-29 Moderna Therapeutics, Inc. Methods and compositions for targeting agents into and across the blood-brain barrier
EP3072898A1 (en) 2012-02-20 2016-09-28 Universita' degli Studi di Milano Homo- and heterodimeric smac mimetic compounds as apoptosis inducers
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
WO2014012051A1 (en) 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
KR102121086B1 (ko) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
EP3417874B1 (en) * 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015014869A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015038892A1 (en) 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
US9950065B2 (en) 2013-09-26 2018-04-24 Biontech Rna Pharmaceuticals Gmbh Particles comprising a shell with RNA
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3052479A4 (en) 2013-10-02 2017-10-25 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
EP3076994A4 (en) 2013-12-06 2017-06-07 Modernatx, Inc. Targeted adaptive vaccines
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
JP2017507703A (ja) 2014-02-05 2017-03-23 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ カニューレ、注射または注入装置、およびカニューレまたは注射もしくは注入装置を使用する方法
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
PT4023755T (pt) 2014-12-12 2023-07-05 CureVac SE Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
EP3240558A1 (en) 2014-12-30 2017-11-08 CureVac AG Artificial nucleic acid molecules
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
MX2018004544A (es) 2015-10-12 2018-11-09 Nantomics Llc Composiciones y métodos para los neoepítopos de cáncer viral.
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CA3060569A1 (en) 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
AU2018279627B2 (en) 2017-06-09 2023-08-10 Seattle Project Corp. Neoantigen identification, manufacture, and use
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US20200363414A1 (en) 2017-09-05 2020-11-19 Gritstone Oncology, Inc. Neoantigen Identification for T-Cell Therapy
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
EP3759131A4 (en) 2018-02-27 2021-12-01 Gritstone bio, Inc. NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS

Also Published As

Publication number Publication date
JP7396903B2 (ja) 2023-12-12
IL271031A (en) 2020-01-30
JP2026041868A (ja) 2026-03-10
IL271031B1 (en) 2025-09-01
CN110741260B (zh) 2024-03-08
US20250283888A1 (en) 2025-09-11
FI3635408T3 (fi) 2025-07-15
HUE072622T2 (hu) 2025-12-28
RU2019139982A (ru) 2021-07-09
US12270813B2 (en) 2025-04-08
AU2018279117B2 (en) 2025-01-30
TW201920959A (zh) 2019-06-01
TWI865429B (zh) 2024-12-11
SI3635408T1 (sl) 2025-08-29
SG10201912475XA (en) 2020-02-27
LT3635408T (lt) 2025-08-11
DK3635408T3 (da) 2025-07-21
TW202426040A (zh) 2024-07-01
EP3635408B1 (en) 2025-04-30
HRP20250791T8 (hr) 2025-11-07
US20200209251A1 (en) 2020-07-02
IL271031B2 (en) 2026-01-01
JP7785735B2 (ja) 2025-12-15
EP4599845A3 (en) 2025-11-19
JP2024026224A (ja) 2024-02-28
KR20200014311A (ko) 2020-02-10
BR112019022349A2 (pt) 2020-05-26
RU2019139982A3 (pt) 2021-07-09
PL3635408T3 (pl) 2025-08-25
MA49246A (fr) 2020-04-15
WO2018224166A1 (en) 2018-12-13
IL322657A (en) 2025-10-01
CN110741260A (zh) 2020-01-31
MX2024014422A (es) 2025-09-02
JP2020523016A (ja) 2020-08-06
EP3635408A1 (en) 2020-04-15
KR102560750B9 (ko) 2025-01-22
SMT202500278T1 (it) 2025-09-12
AR112601A1 (es) 2019-11-20
AU2025203027A1 (en) 2025-06-26
CA3066308A1 (en) 2018-12-13
AU2018279117A1 (en) 2020-01-02
WO2018224405A1 (en) 2018-12-13
SG11201911618UA (en) 2020-01-30
AU2025203027A9 (en) 2026-03-05
HRP20250791T1 (hr) 2025-09-12
RS67008B1 (sr) 2025-08-29
ES3037112T3 (en) 2025-09-29
MX2024006356A (es) 2025-04-02
EP4599845A2 (en) 2025-08-13
KR102560750B1 (ko) 2023-07-27

Similar Documents

Publication Publication Date Title
SG10201912475XA (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
IL262680A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
IL259793A (en) slc45a2 peptides for immunotherapy
IL251571B (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
IL253518B (en) You will notice proteins with a high positive charge
SG10202007893TA (en) Methods of immunotherapy
IL248283B (en) A method for the synthesis of cloprabine
SG11202106249QA (en) Methods for improved immunotherapy
HUE057882T2 (hu) Eljárás karbodiimidek elõállítására
HK40017108B (zh) 用於预测疾病特异性氨基酸修饰用於免疫治疗的可用性的方法
HK40017108A (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
GB201821205D0 (en) Immunotherapy
IL254205B (en) Reagents for the acylation of amino acids and methods for their use